Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

(2010) T. Nakahara et al.   BLOOD

Selective Depletion of CD4+CD25+Foxp3+Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels

(2010) Jie Zhao et al.   CANCER RESEARCH

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

(2009) Vedran Radojcic et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

METRONOMIC CHEMOTHERAPY. CHANGING THE PARADIGM THAT MORE IS BETTER

(2009) O.Graciela Scharovsky et al.   Current Oncology

Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity

(2009) Zuqiang Liu et al.   JOURNAL OF IMMUNOLOGY

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY